Comprehensive Endocrine Cancer Panel
Use
The Comprehensive Endocrine Cancer Panel is designed to assist individuals with a clinical or suspected diagnosis of hereditary endocrine tumor syndromes. It is suitable for patients with a family history of endocrine tumors or cancers and those seeking comprehensive genetic screening specifically for hereditary endocrine and neuroendocrine tumors. This panel can provide insights into genetic predispositions and guide personalized management strategies.
Special Instructions
The test includes a combination of next-generation sequencing (NGS) and copy number variation (CNV) analysis using the PGselect platform. It is important to coordinate with the laboratory for any special billing options like adding exome-wide CNV analysis, which may not be available for some panel types. The test is New York approved, ensuring compliance with state regulations for clinical testing.
Limitations
The test has not been cleared or approved by the US Food and Drug Administration, although it follows CLIA and CAP regulations. It is essential to understand that the test may not detect all genetic alterations associated with endocrine cancers. Variants of unknown significance may require further interpretation, and not all variants are clinically actionable. Environmental and lifestyle factors should also be considered in risk assessments.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided